Niranjan Bhat

Program for Appropriate Technology in Health

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9–14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial”.

Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9–14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial

The Lancet Infectious Diseases(2025)10.1016/s1473-3099(25)00031-3

N/A

0.496DataRank · unranked

10 citations

Anne Schuind, Samuel Adjei, Kalpana Antony, John J. Aponte, Patrick Boakye Yiadom Buabeng +10 more

Assessing the strength of evidence for a causal effect of respiratory syncytial virus lower respiratory tract infections on subsequent wheezing illness: a systematic review and meta-analysis

The Lancet Respiratory Medicine(2020)10.1016/s2213-2600(20)30109-0

N/A

0DataRank · unranked

110 citations

Brittney M. Snyder, Amanda J. Driscoll, Deshayne B. Fell, David A. Savitz, Daniel R. Feikin +11 more